CUPERTINO, Calif., April 24 /PRNewswire Interactive News Release/ — In
conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter financial
results press release, you are invited to listen to its conference call that
will be broadcast live over the Internet on Monday, April 30th, 2001 at 4:30
p.m. EDT with Jim Brown, President and Chief Executive Officer, Tom Schreck,
Chief Financial Officer, and Schond Greenway, Director, Investor Relations.
| What: | DURECT Corporation first quarter earnings conference call |
|---|---|
| When: | Monday, April 30th, 2001, 4:30 p.m. ET |
| Where: | http://www.www.durect.com/wt/frame.php?page_name=investor |
| How: | Live over the Internet — Simply log on to the Web |
| at the address listed above or access through DURECT’s | |
| Website. | |
| Contact: | Andi Wakayama, Noonan/Russo Communications, 415-677-4455, |
| ext. 252 |
DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems that will deliver the right drug to the right site in
the right amount at the right time. DURECT’s pharmaceutical systems combine
technology innovations from the medical device and drug delivery industries
with proprietary pharmaceutical and biotechnology drug formulations. These
capabilities can enable new drug therapies or optimize existing therapies
based on a broad range of compounds, including small molecule pharmaceuticals
as well as biotechnology molecules such as proteins, peptides and genes.
DURECT’s initial portfolio of products combine the DUROS technology, a proven
and patented drug delivery platform licensed for specified fields of use from
ALZA Corporation, with drugs for which medical data on efficacy and safety are
available. Founded in 1998, the Company is headquartered in Cupertino, CA. The
Company’s World Wide Web site can be accessed at http://www.www.durect.com. To
join DURECT’s email alert service, please register by selecting “Email Alerts”
on the main Investor Relations web page at http://www.www.durect.com.
DUROS is a registered trademark of ALZA Corporation.
If you are unable to participate during the live webcast, the call will be
archived at: http://www.www.durect.com/wt/frame.php?page_name=investor
Minimum Requirements to listen to broadcast: The RealPlayer software,
downloadable free from http://www.real.com/products/player/index.html, and at
least a 14.4Kbps connection to the Internet. If you experience problems
listening to the broadcast, send an email to webmaster@vdat.com.)
The statements in this press release regarding DURECT’s products in
development, product development plans, clinical trials, and expected product
benefits are forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties include, but are
not limited to, DURECT’s ability to develop, manufacture and commercialize its
products, complete successful clinical trials, obtain product approvals from
regulatory agencies, build a manufacturing facility, manage its growth and
costs, as well as marketplace acceptance of DURECT’s products. Further
information regarding these and other risks is included in the company’s S-1
registration statement, filed with the SEC on September 22, 2000, 424(b)
prospectus filed with the SEC on September 28, 2000, Quarterly Report on Form
10Q for the quarter ended September 30, 2000 filed with the SEC on November
14, 2000 and Annual Report on Form 10K for the fiscal year ended December 31,
2000 filed with the SEC on March 30, 2001.
MAKE YOUR OPINION COUNT -- Click Here
SOURCE DURECT Corporation
CONTACT: Andi Wakayama, 415-677-4455, ext. 252, for DURECT Corporation/